Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870906 | 0.88 | KMT2A (0.67) | KMT2ASOAT1ADRA1DADRA1AADRA1B | |
| SCHEMBL4881014 | 0.87 | KMT2A (0.57) | KMT2ASOAT1ADRA1DADRA1AADRA1B | |
| SCHEMBL4880432 | 0.84 | KMT2A (0.62) | KMT2ASOAT1ADRA1DADRA1AADRA1B | |
| SCHEMBL5475094 | 0.83 | KMT2A (0.55) | KMT2ASOAT1ADRA1DADRA1AADRA1B | |
| SCHEMBL5480775 | 0.81 | KMT2A (0.57) | KMT2ASOAT1ADRA1DADRA1AADRA1B | |
| SCHEMBL5470593 | 0.81 | KMT2A (0.52) | KMT2AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL4876812 | 0.81 | SOAT1 (0.49) | KMT2ASOAT1DRD2DRD4 | |
| SCHEMBL4873692 | 0.81 | SOAT1 (0.51) | SOAT1DRD2DRD4 | |
| SCHEMBL4876804 | 0.81 | KMT2A (0.66) | KMT2ASOAT1PDE4B | |
| SCHEMBL5470053 | 0.79 | KMT2A (0.55) | KMT2ASOAT1ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | KMT2A 1132/4885SOAT1 502/4885ADRA1D 310/4885 |
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | KMT2A 1301/4885SOAT1 1040/4885ADRA1D 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.